BPGbio Updates on BPM31510 Glioblastoma Trial and Quinomics Study at ESMO 2024

BPGbio, Inc., a leading biopharmaceutical company specializing in mitochondrial biology and protein homeostasis, announced that its researchers will present two posters at the European Society for Medical Oncology (ESMO) Congress 2024, which will be held from September 13-17 in Barcelona. These posters will focus on the ongoing Phase 2 trial of their lead candidate, BPM31510, in patients newly diagnosed with glioblastoma multiforme (GBM).

The principal investigator of the trial, Dr. Seema Nagpal, Clinical Professor of Neurology at Stanford Medicine, will present the latest data from this ongoing trial. The trial has so far enrolled sixteen patients, seven of whom have completed the study. Dr. Nagpal, along with her colleagues at Stanford, will also showcase a detailed quinomics assessment of BPM31510, demonstrating the drug’s in vivo effect on an experimental glioma model and in the human brain, thus validating its metabolic activity.

"We are eager to reveal the latest data from the BPM31510 GBM Phase 2 trial at the ESMO Congress," stated Dr. Seema Nagpal. "Glioblastoma multiforme is one of the most aggressive and lethal brain cancers, and the new data from our clinical research offer significant insights into its treatment."

Professor Lawrence Recht, also from Stanford Medicine, highlighted the importance of their findings, stating, "Observing the metabolic actions of the drug on an aggressive experimental brain tumor and in the brain has uncovered new findings crucial for brain cancer therapy development. We are excited to share this data with our industry peers and fellow researchers."

BPM31510 is being tested in combination with Vitamin K and standard chemoradiation in a single-arm Phase 2b trial across four sites in the United States, targeting a total enrollment of 50 patients. The preliminary results of this trial support BPGbio’s biology-first, AI-driven approach, which aims to optimize patient selection and streamline drug development. Dr. Niven R. Narain, President and CEO of BPGbio, Inc. expressed enthusiasm about the ongoing collaboration with Stanford and other medical centers to complete the trial enrollment.

The ESMO Congress poster presentations are as follows:

1. "Trial in Progress (TiP): A Phase 2 Study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with Vitamin K in combination with Standard of Care (SOC) RT and TMZ in Glioblastoma Multiforme (GBM) patients without prior therapy" will be presented on Monday, September 16, 2024, from 9:00-17:00 CEST. The presentation number is 499TiP, and Dr. Seema Nagpal will be the speaker.

2. "Comprehensive Quinomics Assessment of BPM31510IV Treatment in Advanced Glioblastoma Multiforme Patients" will also be presented on Monday, September 16, 2024, from 9:00-17:00 CEST. The presentation number is 472P, and Dr. Seema Nagpal will be the speaker.

BPM31510 is BPGbio’s leading candidate for the treatment of glioblastoma multiforme and pancreatic cancer. The compound has shown a tolerable safety profile and potential clinical benefit in both patient populations. The mechanism of action of BPM31510 was first validated by data from BPGbio’s NAi Interrogative Biology platform, which indicated a significant shift in the tumor microenvironment induced by BPM31510, modulating mitochondrial oxidative phosphorylation in aggressive tumors. The FDA has granted BPM31510 Orphan Drug Designation for both GBM and pancreatic cancer indications.

Quinomics, the comprehensive measurement of quinone metabolites, is also a focal point of the research. Quinones play essential roles in antioxidant status, mitochondrial function, redox balance, and coagulation status.

BPGbio is a pioneering biopharmaceutical company leveraging a biology-first approach powered by AI. With a robust pipeline of AI-developed therapeutics spanning oncology, rare diseases, and neurology, the company is advancing several candidates through late-stage clinical trials. BPGbio's innovative approach is supported by its proprietary Interrogative Biology Platform, a vast biobank, and access to powerful computational resources. Based in greater Boston, BPGbio is at the forefront of integrating biology, multi-modal data, and AI to revolutionize disease understanding, diagnosis, and treatment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!